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ABSTRACT
Computational methods have traditionally struggled
to predict the effect of mutations in antibody–antigen
complexes on binding affinity. This has limited their
usefulness during antibody engineering and devel-
opment, and their ability to predict biologically rel-
evant escape mutations. Here we present mCSM-
AB, a user-friendly web server for accurately pre-
dicting antibody–antigen affinity changes upon mu-
tation which relies on graph-based signatures. We
show that mCSM-AB performs better than compara-
ble methods that have been previously used for anti-
body engineering. mCSM-AB web server is available
at http://structure.bioc.cam.ac.uk/mcsm ab.
INTRODUCTION
Antibodies (Abs) are a central component of our immune
system, generally recognizing a given antigen through vari-
able loops of -strands known as the complementarity de-
termining regions (CDR’s). This allows Abs to bind to a
wide range of targets with high specificity, including those
typically viewed as undruggable, which has been widely ex-
ploited experimentally, diagnostically and therapeutically.
Mutations within the CDR’s are important for determin-
ing the Abs specificity and affinity, however, like any thera-
peutic treatment, they can exert a selective pressure leading
to the development of escape mutations, which are muta-
tions typically located in the antigen, leading to reducedAb-
binding affinity. Engineering Abs often requires optimiza-
tion of not just selectivity and affinity for the given antigen,
but also stability, solubility and immunogenicity of the Ab
(1). Optimization of these properties is essential not only
for therapeutic use (2,3), but to improve quality and repro-
ducibility in experimental settings (4).
A number of computational methods have been used to
design and optimize Abs (5–8), normally using an avail-
able crystal structure, however accurate prediction of the ef-
fect of a mutation on the free energy of protein binding is
non-trivial. This was highlighted recently by Sirin et al.who
compiled an experimental dataset to benchmark these avail-
able methods, showing that there is still significant room
for improvement, with the best methods only able to iden-
tify a third of mutations that improved binding. We have
previously shown that using graph-based signatures to rep-
resent the 3D wild-type physicochemical and geometrical
environment of a residue we could accurately predict the ef-
fects ofmutations on protein stability, protein–protein affin-
ity, protein–nucleic acid affinity and most recently protein–
smallmolecule affinity (9–12). These have provided valuable
insights into the effects of mutations in a variety of biolog-
ical scenarios (13–16).
An accurate, robust and scalable computational ap-
proach would have enormous implications for not only di-
recting Ab development, but in understanding the evolu-
tion and treatment of escape mutations, including through
optimized vaccine design. We have therefore benchmarked
our existing general methodologies against computational
approaches for Ab engineering, and trained a novel Ab-
specific predictor using the mCSM graph-based signatures
concept in order to account for the unique and highly flex-
ible recognition of Abs: mCSM-AB.
MATERIALS AND METHODS
Datasets
To assess the applicability of mCSM signatures in pre-
dicting the impact of mutations on Ab–antigen affinity, a
dataset derived from the AB-Bind Database was consid-
ered (17). AB-Bind Database is a collection of experimental
thermodynamic parameters for wild-type and mutant Abs
and antigens, including the change in Gibbs free energy of
binding (G), linked to published crystal structures of the
complexes. A total of 645 single-point mutations on 29 dif-
ferent Ab–antigen complexes were considered, five of which
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Figure 1. mCSM-AB workflow and application. (A) from a single-point mutation on a Ab-antigen complex, mCSM-AB extracts the wild-type residue
environment from which a structural signature will be derived as well as a pharmacophore count difference between wild-type and mutant residue. These
information, together with experimentally measured effects of mutations on Ab-antigen affinity from the literature are used as evidence to train and test a
predictive model using machine learning. (B) shows a heatmap of predicted effects by mCSM-AB of all mutations on the complex formed by the VRC01
Ab and the HIV-1 gp120 (based on the PDB: 3NGB). Residues are coloured from white to red, with red being the residues with lower average prediction
(most destabilizing ones).
were homology models, kindly provided by the AB-Bind
database authors. Supplementary Figure S1 of Supplemen-
tary Data shows the experimental G distributions for
themutations in this dataset, which is skewed towardsmuta-
tions that destabilizeAb-binding affinity. This is a limitation
that affects the development of machine learning methods.
In order to avoid any bias caused by this, within the train-
ing and test sets we have included models of the mutations
(obtained using Modeller (18)) in order to consider the hy-
pothetical reverse mutation (mutant to wild-type). This ap-
proach was initially proposed by (19) in order to better bal-
ance experimental observations where there is natural bias
in the distribution of experimental observations, avoiding
the subsequent bias in the computational models.
Low-redundancy datasets
In order to reduce the chance of overfitting while training
the predictive models and enhance their generalization, a
procedure for reducing redundancy between cross valida-
tion folds was employed. Training and test sets for each
fold were divided in a way that all mutations in a given
residue position would only be present in either training or
test set. The resulting low-redundancy sets are available at
http://structure.bioc.cam.ac.uk/mcsm ab/data.
Graph-based structural signatures
Our approach uses a graph-based structural signature for
Ab–antigen complexes that models both the geometry and
physicochemical properties of the interactions and archi-
tecture of the wild-type Ab–antigen complex by represent-
ing atoms as nodes and interactions between them as edges.
From this representation, distance patterns between atoms
categorized by their properties are summarized in con-
cise signatures as cumulative distributions and used as evi-
dence for machine learning methods. Figure 1A depicts the
mCSM-AB prediction workflow. Machine learning meth-
ods, evaluation procedures and performance metrics used
are described in Supplementary Data.
WEB SERVER
We have implemented mCSM-AB via a user-friendly web
server freely available at http://structure.bioc.cam.ac.uk/
mcsm ab. The server front-end was built using Bootstrap
framework version 2.0, while the back-end was built in
Python via the Flask framework (version 0.10.1), running
on a Linux server.
Input
As shown in the job submission interface (Supplementary
Figure S1), mCSM-AB allows users to upload Ab–antigen
complexes (in PDB format) and inform mutations (a single
mutation or a list), on either the Ab or antigen, for which
the impact on antigen affinity can be predicted. The mu-
tation information is given as the residue position, wild-
type and mutant residue codes in one-letter format and
chain identifier. The predictions are performed as a regres-
sion task (numerical prediction of the difference in Gibbs
free energy––G). In order to aid users to submit jobs
to mCSM-AB and interpret its predictions, a help page has
been implemented and is accessible via the top navigation
bar.
Output
Figure 2 shows the result page for predicting the effect of a
single mutation as a regression task. The predicted change
in Gibbs Free Energy uponmutation (G in Kcal/mol) is
given (i) as well as the identification of the provided muta-
tion (ii) and a GLMol-based visualization of the mutated
residue in the Ab–antigen structural environment (iii). A
negative value (and red writing) corresponds to a mutation
predicted as reducing affinity; while a positive sign (and blue
writing) corresponds to a mutation predicted as increasing
affinity. For classification tasks, the server will predict the
mutation as either reducing or increasing affinity.
The result page for predicting effects of a list of mutations
(Supplementary Figure S2) is given in a tabular format, con-
taining the identification of themutation, its residue relative
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Figure 2. Web server result page. The figure depicts the result page for the single mutation prediction mode for mCSM-AB, which shows the numerical
prediction (1), mutation information (2) and an interactive GLMol session of the residue structural location (3).
solvent accessibility, predicted G or direction of change
(increase/decrease affinity). An option to download the re-
sults as a tab-separated file is also available.
VALIDATION
Comparison with well established methods
As highlighted in Sirin et al. (17), the leading computa-
tional approaches for Ab engineering struggled to iden-
tify a majority of mutations leading to improved antigen
affinity. We have previously published and characterized a
machine learning method using graph-based signature to
predict the effects of mutations on protein–protein bind-
ing affinities, mCSM-PPI (20). The benchmarking database
used by Sirin et al. comprised of 29 Ab–antigen structures
where the antigens were comprised of protein and peptide
chains. We therefore evaluated the ability of mCSM-PPI
to accurately predict the effects of mutations in these Ab–
antigen complexes. mCSM-PPI performed as well as the
leading methodologies analysed by Sirin et al., achieving a
Pearson’s correlation of r = 0.36. This highlights the ability
of graph-based signatures to model the effects of mutations
without the need to explicitly consider the effects of solva-
tion, unlike methods relying on free energy perturbation,
thermodynamic integration and empirical models where it
needs to be considered for accuracy. mCSM-PPI is there-
fore significantly less computationally demanding, and can
be run rapidly without the associated loss in accuracy.
Based on these promising results, we hypothesized that it
might be more accurate and appropriate to build a graph-
based methodology tailored specifically to consider the
unique interaction interfaces presented by Abs (21), along
with the more specialized cases where the antigen is a pep-
tide (22–24), than a generalized PPI methodology where
these types of interactions are underrepresented. We there-
fore built and trained a novel predictor: mCSM-AB.
mCSM-AB performed significantly better than the meth-
ods evaluated by Sirin et al., achieving a Pearson’s cor-
relation of r = 0.53 on regression tasks on 10-fold cross
validation, considering a low-redundancy dataset, with a
standard deviation of 1.981. Figure 3 shows the regression
plots between experimental and predicted affinity changes
obtained for the original AB-Bind dataset (left-hand side)
and for new method that also includes the models of the
hypothetical reverse mutations (right-hand side). Table 1
presents a comparison of the performances between the
considered methods. It is interesting to notice that the
mCSM-AB was superior to most the compared methods,
showcasing prediction capabilities of the proposed mCSM-
AB platform.
The mCSM-AB predictive model built using the hypo-
thetical reverse mutations was more robust and accurate
than the model built using just the experimental observa-
tions. While the Pearson’s correlations were not statistically
different from the model trained with the original dataset,
its ability to differentiate mutations that enhance or reduce
binding affinity was significantly improved.
During cross validation, mCSM-AB achieved correla-
tions of 0.32 and 0.30 for mutations increasing and decreas-
ing affinity , respectively. It is important to point out, that
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Figure 3. Regression plot between the experimental and predicted affinity change in Kcal/mol. mCSM-AB obtained a Pearson’s correlation of 0.52 on the
original dataset (left) and 0.53 on the dataset including hypothetical reverse mutations.
Table 1. Performance comparison of available methods and mCSM-AB
in classifying the direction of the change in Ab-antigen affinity caused by
a mutation
Method Pearson’s coefficient
bASA 0.22
dDFIRE 0.19
DFIRE 0.31
STATIUM 0.32
Rosetta 0.16
FoldX 0.34
Discovery Studio 0.45
mCSM-PPI 0.35
mCSM-AB 0.53/0.56a
aPerformance removing non-binders, variants determined not to bind
within the sensitivity of the assay, for which G was set to −8 Kcal/mol
(17).
The performance of the available methods are from Sirin etal. (17).
even though the correlations were lower than the complete
dataset, mCSM-AB still correctly assigns the direction of
the change for 77 and 76% of the increasing and decreasing
affinity mutations, respectively.
Blind test validation on homology models
In the original dataset proposed by (17), there were 5 Ab–
antigen homology model complexes, containing 87 muta-
tions in total. Of thesemutations,∼63% (55mutations) lead
to a decrease in experimental binding affinity, whilst 37%
(32 mutations) had been shown experimentally to increase
binding affinities. The hypothetical reverse mutations were
also included, generating a balanced dataset. These were
therefore removed from the mCSM-AB training set, which
therefore was trained on experimental structures only, and
used to evaluate the final models.
The model achieved a Pearson’s correlation of 0.45 with
the experimentally measured affinities of the homology
modelled complexes. mCSM-AB presented a slightly lower
performance than in cross validation, but with a lower stan-
dard deviation (1.30), which provides confidence in the ap-
plicability of this approach beyond experimental structures
to those that are computationallymodelled. Supplementary
Table S1 shows the performance of mCSM-AB per homol-
ogy model.
Predicting HIV-1 escape mutations
We also wanted to evaluate the applicability of these models
outside of experimentally measured affinities to biological
systems, in particular the development of escape mutations
that hinder the usefulness of therapeutic Abs. For this eval-
uation we used the anti-HIV therapeutic Ab VRC01, which
recognizes theHIV-1 envelope glycoprotein gp120 complex.
The effect of 78 distinct mutations upon the effectiveness of
VRC01 had been studied in (25). Of these mutations, 33 in-
creased and 45 decreased HIV-1 sensitivity to this neutral-
ization Ab. Using the experimental crystal structure of the
VRC01–p120 complex (PDB ID: 3NGB), we testedwhether
mCSM-AB could correctly classify those mutations which
resulted in reduced effectiveness of VRC01.mCSM-ABpre-
dictions correlated strongly to the biological measurements,
with a Pearson’s correlation of 0.51 (and consistent with
performance on the AB-Bind database). This highlighted
the potential predictive power of this approach for explor-
ing the consequences of biologically and clinically relevant
mutations.
We therefore expanded our analysis by performing com-
putational saturation mutagenesis of the entire gp120 struc-
ture and mapping the average predicted changes in binding
affinity onto the structure (Figure 1B). This could be of sig-
nificant help in identifying regions more likely to lead to de-
velop escape mutations against Ab therapy, and help guide
design and development strategies.
mCSM-AB has also been further validated on a dataset
of 114 mutations on 4 Ab/antigen complexes (228, includ-
ing hypothetical reverse mutations) from (26), achieving a
correlation of 0.67, as described in Supplementary Data.
CONCLUSIONS
We present here a new approach, mCSM-AB, which relies
upon graph-based signatures to predict the impact of mis-
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sense mutations upon the binding affinity of an Ab for a
given antigen. The results achieved by mCSM-AB support
the idea that themolecular shape and physicochemical com-
plementarity, driving forces guiding molecular recognition
on Ab–antigen complexes can be modelled and its deter-
minant features mined with structural signatures. This al-
lowed us to tailor a new method to accurately and robustly
predict the effects of mutations. We believe that mCSM-AB
will be a useful tool in the design and development of thera-
peutic and diagnostic Abs, and could provide useful insight
into the development of escape mutations. A web server im-
plementing mCSM-AB functionality is freely available at
http://structure.bioc.cam.ac.uk/mcsm ab.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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